

10-19-05

JC04 Rec'd PCT/PTO 17 OCT 2005



PATENT DOCKET 206,953

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

DE LUCA ET AL.

EXAMINER:

SERIAL NO.:

10/531,853

ART UNIT:

FILED:

April 18, 2005

FOR:

TAXANES COVALENTLY  
BOUNDED TO HYALURONIC  
ACID OR HYALURONIC  
ACID DERIVATIVES

Honorable Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

October 17, 2005

**RESPONSE TO NOTIFICATION TO COMPLY  
WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES**

**STATEMENT OF FILING BY EXPRESS MAIL 37 C.F.R. § 1.10**

This correspondence is being deposited with the United States Postal Service on October 17, 2005 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ER 842053 385 US addressed to the Honorable Commissioner for Patents, Washington, D.C. 20231.


**REMARKS**

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures of September 23, 2005, copy enclosed, Applicants have carefully reviewed the as-filed specification and cannot identify any disclosure or material which would require a "Sequence Listing".

It is respectfully submitted that the Notification to Comply is in error and should be withdrawn.


Please charge any fees which may be due which have not been submitted herewith to our Deposit Account No. 01-0035.

Respectfully submitted,



JAY S. CINAMON  
Attorney for Applicants  
Registration No. 24,156

**ABELMAN, FRAYNE & SCHWAB**  
666 Third Avenue  
New York, NY 10017  
(212) 949-9022



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/531,853	Gilda De Luca	206,953
DUE BY <u>11/23/05</u>		INTERNATIONAL APPLICATION NO.
		PCT/EP03/11239
Abelman Franye & Schwab DOCKETED ON <u>10/3/05</u>		I.A. FILING DATE
		10/10/2003
DOCKETED WITHOUT FILE		PRIORITY DATE
		10/18/2002
ATTORNEY <u>J.S.C.</u>		
CONFIRMATION NO. 3983		
371 FORMALITIES LETTER		
		
*OC000000017091373*		

Date Mailed: 09/23/2005

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice MUST be returned with the response.*

BARBARA A CAMPBELL

---

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/531,853	PCT/EP03/11239	206,953

FORM PCT/DO/EO/922 (371 Formalities Notice)